Skin will naturally lose elasticity over time
On the reverse side, researchers found GLP-1 use was associated with an increased risk of gastrointestinal problems, including nausea, vomiting, diarrhea, and, in rare cases, paralysis of the stomach
Semaglutide was added to WADAs Monitoring Program in 2024, with tirzepatide following in 2025
This dose won't produce significant weight loss on its own
Survodutide Active Compound is the Fastest Growing Segment of the GLP-1 Market During the Forecast Period Based on the active compound, the market is segmented into dulaglutide, liraglutide, orforglipron, retatrutide, semaglutide, survodutide, tirzepatide and other active compounds
PlexusDx helps patients understand their genetic predispositions in peptide signaling pathways and discuss these insights with their healthcare provider to select a medication formulation and dosing strategy aligned with their personal tolerability profile